Does the media prefer BEAM or DNLI?

In the previous week, Beam Therapeutics had 24 more articles in the media than Denali Therapeutics. MarketBeat recorded 26 mentions for Beam Therapeutics and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.46 beat Beam Therapeutics' score of 0.49 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SMMT or DNLI more profitable?

Denali Therapeutics' return on equity of -55.27% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Denali Therapeutics N/A -55.27% -44.24%

Does the media prefer SMMT or DNLI?

In the previous week, Summit Therapeutics had 7 more articles in the media than Denali Therapeutics. MarketBeat recorded 9 mentions for Summit Therapeutics and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.46 beat Summit Therapeutics' score of 1.12 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BMRN or DNLI?

In the previous week, BioMarin Pharmaceutical had 17 more articles in the media than Denali Therapeutics. MarketBeat recorded 19 mentions for BioMarin Pharmaceutical and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.46 beat BioMarin Pharmaceutical's score of 0.77 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 8 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HALO or DNLI?

In the previous week, Halozyme Therapeutics had 11 more articles in the media than Denali Therapeutics. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.46 beat Halozyme Therapeutics' score of 1.20 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DNLI or MDGL?

In the previous week, Madrigal Pharmaceuticals had 8 more articles in the media than Denali Therapeutics. MarketBeat recorded 10 mentions for Madrigal Pharmaceuticals and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.46 beat Madrigal Pharmaceuticals' score of 0.82 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Denali Therapeutics (DNLI) Competitors

$21.09 -0.31 (-1.45%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$21.21 +0.12 (+0.56%)

As of 09/11/2026 07:59 PM Eastern

Compare

DNLI vs. BEAM, SMMT, BMRN, HALO, and MDGL

Should you buy Denali Therapeutics stock or one of its competitors? Denali Therapeutics's main competitors and comparable companies include Beam Therapeutics (BEAM), Summit Therapeutics (SMMT), BioMarin Pharmaceutical (BMRN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Denali Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Beam Therapeutics currently has a consensus target price of $49.00, suggesting a potential upside of 104.25%. Denali Therapeutics has a consensus target price of $35.85, suggesting a potential upside of 69.97%. Given Beam Therapeutics' higher possible upside, research analysts plainly believe Beam Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Beam Therapeutics has a beta of 2.22, meaning that its share price is 122% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Denali Therapeutics	N/A	-55.27%	-44.24%

Beam Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$156.04M	15.88	-$79.99M	-$0.86	N/A
Denali Therapeutics	$330.53M	10.20	-$512.54M	-$2.84	N/A

In the previous week, Beam Therapeutics had 24 more articles in the media than Denali Therapeutics. MarketBeat recorded 26 mentions for Beam Therapeutics and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.46 beat Beam Therapeutics' score of 0.49 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beam Therapeutics beats Denali Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by insiders. Comparatively, 9.7% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summit Therapeutics presently has a consensus price target of $25.91, suggesting a potential upside of 47.63%. Denali Therapeutics has a consensus price target of $35.85, suggesting a potential upside of 69.97%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Denali Therapeutics' return on equity of -55.27% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Denali Therapeutics	N/A	-55.27%	-44.24%

In the previous week, Summit Therapeutics had 7 more articles in the media than Denali Therapeutics. MarketBeat recorded 9 mentions for Summit Therapeutics and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.46 beat Summit Therapeutics' score of 1.12 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Denali Therapeutics	$330.53M	10.20	-$512.54M	-$2.84	N/A

Summit Therapeutics has a beta of -1.24, meaning that its stock price is 224% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

Summary

Denali Therapeutics beats Summit Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Denali Therapeutics compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Denali Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Denali Therapeutics	N/A	-55.27%	-44.24%

In the previous week, BioMarin Pharmaceutical had 17 more articles in the media than Denali Therapeutics. MarketBeat recorded 19 mentions for BioMarin Pharmaceutical and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.46 beat BioMarin Pharmaceutical's score of 0.77 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	8 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market.

BioMarin Pharmaceutical has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.95	$348.90M	$0.37	177.51
Denali Therapeutics	$330.53M	10.20	-$512.54M	-$2.84	N/A

BioMarin Pharmaceutical currently has a consensus target price of $89.17, indicating a potential upside of 35.77%. Denali Therapeutics has a consensus target price of $35.85, indicating a potential upside of 69.97%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Denali Therapeutics is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	2.74
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

BioMarin Pharmaceutical beats Denali Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Denali Therapeutics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Halozyme Therapeutics has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.71	$316.89M	$3.35	32.00
Denali Therapeutics	$330.53M	10.20	-$512.54M	-$2.84	N/A

Halozyme Therapeutics presently has a consensus price target of $91.20, indicating a potential downside of 14.93%. Denali Therapeutics has a consensus price target of $35.85, indicating a potential upside of 69.97%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Denali Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Halozyme Therapeutics has a net margin of 24.86% compared to Denali Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Denali Therapeutics	N/A	-55.27%	-44.24%

In the previous week, Halozyme Therapeutics had 11 more articles in the media than Denali Therapeutics. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.46 beat Halozyme Therapeutics' score of 1.20 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market.

Summary

Halozyme Therapeutics beats Denali Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to Madrigal Pharmaceuticals?

Denali Therapeutics (NASDAQ:DNLI) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

In the previous week, Madrigal Pharmaceuticals had 8 more articles in the media than Denali Therapeutics. MarketBeat recorded 10 mentions for Madrigal Pharmaceuticals and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.46 beat Madrigal Pharmaceuticals' score of 0.82 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics presently has a consensus price target of $35.85, suggesting a potential upside of 69.97%. Madrigal Pharmaceuticals has a consensus price target of $699.64, suggesting a potential upside of 30.90%. Given Denali Therapeutics' higher probable upside, equities research analysts clearly believe Denali Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Madrigal Pharmaceuticals has higher revenue and earnings than Denali Therapeutics. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	10.20	-$512.54M	-$2.84	N/A
Madrigal Pharmaceuticals	$958.40M	12.88	-$288.28M	-$12.89	N/A

Denali Therapeutics has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, indicating that its share price is 198% less volatile than the broader market.

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Denali Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Denali Therapeutics' return on equity of -55.27% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Summary

Madrigal Pharmaceuticals beats Denali Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Denali Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNLI vs. The Competition

Export

Metric	Denali Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.42B	$3.85B	$7.15B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-7.43	14.18	274.95	25.29
Price / Sales	10.20	1,477.55	656.56	98.96
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	3.05	15.12	10.33	6.20
Net Income	-$512.54M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-5.34%	-4.34%	-3.32%	-2.35%
1 Month Performance	-16.54%	-0.02%	-0.41%	-2.77%
1 Year Performance	48.63%	40.64%	19.21%	7.63%

Denali Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNLI Denali Therapeutics	3.7574 of 5 stars	$21.09 -1.4%	$35.85 +70.0%	+42.3%	$3.42B	$330.53M	N/A	507	Positive News
BEAM Beam Therapeutics	2.3477 of 5 stars	$29.66 flat	$49.00 +65.2%	+11.3%	$3.06B	$139.74M	N/A	510	Trending News Analyst Forecast Options Volume
SMMT Summit Therapeutics	3.6748 of 5 stars	$17.60 flat	$24.07 +36.8%	-5.6%	$14.04B	N/A	N/A	110	Positive News Analyst Forecast
BMRN BioMarin Pharmaceutical	4.6226 of 5 stars	$66.53 flat	$89.17 +34.0%	+17.5%	$12.88B	$3.22B	179.81	3,221	Analyst Forecast
HALO Halozyme Therapeutics	3.1798 of 5 stars	$110.19 flat	$91.20 -17.2%	+38.3%	$12.51B	$1.40B	32.89	390	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DNLI) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Denali Therapeutics (DNLI) Competitors

DNLI vs. BEAM, SMMT, BMRN, HALO, and MDGL

How does Denali Therapeutics compare to Beam Therapeutics?

Summary

How does Denali Therapeutics compare to Summit Therapeutics?

Summary

How does Denali Therapeutics compare to BioMarin Pharmaceutical?

Summary

How does Denali Therapeutics compare to Halozyme Therapeutics?

Summary

How does Denali Therapeutics compare to Madrigal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI vs. The Competition

Denali Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Denali Therapeutics (DNLI) Competitors

DNLI vs. BEAM, SMMT, BMRN, HALO, and MDGL

How does Denali Therapeutics compare to Beam Therapeutics?

Do analysts recommend BEAM or DNLI?

Which has more risk & volatility, BEAM or DNLI?

Do institutionals and insiders hold more shares of BEAM or DNLI?

Is BEAM or DNLI more profitable?

Which has better valuation & earnings, BEAM or DNLI?

Does the media prefer BEAM or DNLI?

Summary

How does Denali Therapeutics compare to Summit Therapeutics?

Do institutionals & insiders hold more shares of SMMT or DNLI?

Do analysts recommend SMMT or DNLI?

Is SMMT or DNLI more profitable?

Does the media prefer SMMT or DNLI?

Which has higher earnings and valuation, SMMT or DNLI?

Which has more volatility & risk, SMMT or DNLI?

Summary

How does Denali Therapeutics compare to BioMarin Pharmaceutical?

Do institutionals & insiders believe in BMRN or DNLI?

Is BMRN or DNLI more profitable?

Does the media prefer BMRN or DNLI?

Which has more volatility and risk, BMRN or DNLI?

Which has stronger earnings & valuation, BMRN or DNLI?

Do analysts rate BMRN or DNLI?

Summary

How does Denali Therapeutics compare to Halozyme Therapeutics?

Do insiders & institutionals believe in HALO or DNLI?

Which has higher valuation & earnings, HALO or DNLI?

Do analysts rate HALO or DNLI?

Is HALO or DNLI more profitable?

Does the media prefer HALO or DNLI?

Which has more risk & volatility, HALO or DNLI?

Summary

How does Denali Therapeutics compare to Madrigal Pharmaceuticals?

Does the media prefer DNLI or MDGL?

Do analysts rate DNLI or MDGL?

Which has higher earnings & valuation, DNLI or MDGL?

Which has more volatility & risk, DNLI or MDGL?

Do institutionals and insiders have more ownership in DNLI or MDGL?

Is DNLI or MDGL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI vs. The Competition

Denali Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools